PARP Inhibitors in Breast Cancer: Why, How, and When?
Breast Care (Basel)
.
2018 Jul;13(3):216-219.
doi: 10.1159/000490746.
Epub 2018 Jun 20.
Authors
Angelo Paradiso
1
,
Eleni Andreopoulou
2
,
Pierfranco Conte
3
4
,
Alexandru Eniu
5
,
Mahasti Saghatchian
6
Affiliations
1
Experimental Medical Oncology, Istituto Tumori G. Paolo II, IRCCS, Bari, Italy.
2
Weill Cornell Breast Center, Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, NY, USA.
3
Department of Surgery, Oncology and Gastroenterology, University of Padova, Padua, Italy.
4
Division of Medical Oncology 2, Istituto Oncologico Veneto IRCCS, Padua, Italy.
5
Department of Breast Tumors, Cancer Institute 'Ion Chiricuta', Cluj-Napoca, Romania.
6
Breast Cancer Unit, American Hospital of Paris, Neuilly-sur-Seine, France.
PMID:
30069183
PMCID:
PMC6062717
DOI:
10.1159/000490746
No abstract available